Share This Article:

Comparative Rates of Adverse Events with 2-Hour versus 4-Hour Infusion of Total Dose Intravenous Iron Polymaltose

Abstract Full-Text HTML Download Download as PDF (Size:79KB) PP. 145-148
DOI: 10.4236/ijcm.2014.54025    2,749 Downloads   3,840 Views   Citations


Background and aim of the study: Patients with iron deficiency (ID) who are unable to tolerate or show sub-optimal response to oral iron therapy are candidates for parenteral iron therapy. This study evaluated the patient safety and tolerance of iron polymaltose given either as a 2-hour infusion or as a 4-hour infusion. Methods: A total of 243 patients with ID were randomized alternatively to receive iron polymaltose infusion either as a 2-hour infusion or as a 4-hour infusion. All patients received pre-medication with certizine hydrochloride 10 mg PO one-hour before infusion and hydrocortisone 50 mg IVI immediately before infusion. Infusion related adverse events/side-effects during the infusion and over the next seven days were documented and graded as mild, moderate or severe. Results: The age of the patients ranged from 17 years to 92 years (mean 55.5 yr); M:F = 1:3.5. One hundred and twenty-two patients were in the 2-hour arm (M:F = 1:5; mean age 52.9 yr) and 121 were in the 4-hour arm (M:F = 1:2.6; mean age 58.1 yr). Iron infusion therapy was generally well tolerated by patients in both arms. Adverse events/side effects were documented in 14 patients in each arm (22 events in the 2-hour arm and 20 in the 4-hour arm) and included aches and pains, cannula-site pain/swelling, nausea, abdominal cramps, rash, vagal response, metallic taste, hot flushes and headaches. In most patients, these events were mild and none had any severe events. Conclusion: The incidence of adverse events with 2-hour infusion of iron polymaltose is similar to that observed with 4-hour infusion of iron polymaltose.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. Manoharan, W. Alexander, R. Ramakrishna, J. Legge and J. Uebel, "Comparative Rates of Adverse Events with 2-Hour versus 4-Hour Infusion of Total Dose Intravenous Iron Polymaltose," International Journal of Clinical Medicine, Vol. 5 No. 4, 2014, pp. 145-148. doi: 10.4236/ijcm.2014.54025.


[1] E. Beutler, “Disorders of Iron Metabolism in Williams Hematology,” In: M. A. Lichtman, E. Beutler, T. J. Kipps, U. Seligsohn, K. Kaushansky and J. F. Prchol, Eds., Williams Hematology, Mc-Graw-Hill, New York, 2006, p. 518.
[2] M. B. Zimmermann and R. F. Hurrell, “Nutritional Iron Deficiency,” Lancet, Vol. 370, No. 9586, 2007, pp. 511-520.
[3] A. Daniilidis, A. Giannoulis and C. Pantelis, et al., “Total Infusion of Low Molecular Weight Iron-Dextran for Treating Post-Partum Anemia,” Clinical and Experimental Obstetrics and Gynecology, Vol. 38, No. 2, 2011, pp. 159-161.
[4] F. Beigel, B. Lohn, R. P. Laubender, et al., “Iron Status and Analysis of Efficacy and Safety of Ferric Carboxymaltose Treatment in Patients with Inflammatory Bowel Disease,” Digestion, Vol. 85, 2012, pp. 47-54.
[5] M. L. Haines and P. R. Gibson, “Delayed Reactions to Total Dose Intravenous Iron Polymaltose,” Internal Medicine Journal, Vol. 39, No. 4, 2009, pp. 252-255.
[6] A. Manoharan, R. Ramakrishna and B. Pereira, “Delayed Adverse Reactions to Total-Dose Intravenous Iron Polymaltose,” Internal Medicine Journal, Vol. 39, No. 12, 2009, p. 857.
[7] M. Garg, G. Morrison, A. Friedman, A. Lau, D. Lau and P. R. Gibson, “A Rapid Infusion Protocol Is Safe for Total Dose Iron Polymaltose: Time for Change,” Internal Medicine Journal, Vol. 41, No. 7, 2011 pp. 548-554.
[8] E. Newnham, I. Ahmad, A. Thornton and P. R. Gibson, “Safety of Iron Polymaltose Given as a Total Dose Iron Infusion,” Internal Medicine Journal, Vol. 36, No. 10, 2006, pp. 672-674.
[9] Department of Health, “Guiding Principles for the Development of Intravenous (IV) Iron Infusion Practice,” Department of Health, Victoria, 2013.
[10] “Product Information: Ferinject (Ferric Carboxymaltose) Vifor Pharma/Aspen Australia,” 2012.
[11] M. Naim and J. Hunter, “Intravenous Iron Replacement Management in General Practice,” Australian Family Physician, Vol. 39, No. 11, 2010, pp. 839-841.
[12] A. K. Alhossain and A. E. Dennis, “Iron Deficiency Anaemia in Pregnancy and Postpartum: Pathophysiology and Use of Oral versus Intravenous Iron Therapy,” Journal of Pregnancy, 2012, Article ID: 630519.

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.